IL2 and neoplasm: We had previously reported CD25 Mab, an afucosylated, IL-2 non-blocking human IgG1 antibody, that was shown to efficiently deplete Tregs in humans and solid tumor bearing mice (15, 16), while allowing binding of IL-2 to effector T cells and the formation of anti-tumor adaptive immune responses (17).